Clinical trials: Schizophrenia Spectrum Disorders
Schizophrenia, Cognition
Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia
The investigators propose to test whether curcumin nanoparticles will improve behavioral measures and biomarkers of cognition and neuroplasticity in patients with schizophrenia who are already receiving a stable dose of…
- Conditions
- Schizophrenia, Cognition, Psychosis
- Trial name
- NCT02104752
- Testing
- Curcumin
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- VA Greater Los Angeles Healthcare System
Schizophrenia
Study Evaluating Vabicaserin in Subjects With Schizophrenia
The primary purpose of this protocol is to establish the efficacy, safety, and tolerability of vabicaserin (SCA-136) using a once a day capsule in subjects with acute exacerbations of schizophrenia.
- Trial name
- NCT00563706
- Testing
- vabicaserin, risperidone
- Where
- 33 sites in United States, Canada
- Volunteers
- 199 people
- Sponsor
- Pfizer
Psychosis
The Relationship Between Autobiographical Memory and Motivation
People with a diagnosis of psychosis often experience low motivation and pleasure when thinking about doing future activities. This leads, quite understandably, to doing fewer activities they used to enjoy and not taking up…
- Trial name
- NCT03677635
- Testing
- Guided Autobiographical Memory Recall
- Where
- 2 sites in United Kingdom
- Volunteers
- 31 people
- Sponsor
- King's College London
Schizophrenia
Transcranial Magnetic Stimulation for the Treatment of Auditory Hallucinations in Schizophrenia
Repetitive transcranial magnetic stimulation (rTMS) is a new noninvasive therapy that uses magnetic energy applied to the scalp to modulate activity in the underlying regions of the brain.
- Trial name
- NCT01595503
- Testing
- rTMS with fMRI-based targeting, rTMS with landmark-based targeting
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Michigan
Schizophrenia, Schizoaffective Disorder
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Varenicline (Chantix) is a smoking cessation treatment that was approved in 2006 by the FDA for treatment of nicotine dependence and may be particularly beneficial in smokers with schizophrenia or bipolar disorder.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Smoking
- Trial name
- SCRP (NCT00621777)
- Testing
- Varenicline
- Where
- 10 sites in United States
- Volunteers
- 247 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia, Schizophrenic Disorders
Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.
The purpose of this open-label study is to evaluate the long-term (6-month) safety and tolerability of extended-release paliperidone, an atypical antipsychotic, given in flexible dosages to adolescents with schizophrenia.
- Conditions
- Schizophrenia, Schizophrenic Disorders, Psychotic Disorders, Dementia Praecox
- Trial name
- NCT00488319
- Testing
- Paliperidone ER
- Where
- 53 sites in United States, Belgium and 9 more
- Volunteers
- 400 people
- Sponsor
- Janssen Research & Development, LLC
Schizophrenia, Schizoaffective Disorder
Treatment of Negative Symptoms of Schizophrenia With Transcranial Magnetic Stimulation (TMS)
This study will test whether repetitive transcranial magnetic stimulation (rTMS) is helpful in treating negative symptoms and social deficits of schizophrenia.
- Trial name
- NCT00517075
- Testing
- Transcranial Magnetic Stimulation (TMS), repetitive transcranial magnetic stimulation
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- New York State Psychiatric Institute
Severe Mental Illness, Nicotine Dependence
Electronic Decision Support Systems for Smokers With Severe Mental Illness
This randomized clinical trial among SMI smokers assessed whether the EDSS with carbon monoxide monitor and health-checklist feedback lead to higher rates of initiation of smoking cessation treatment, days of smoking abstinence…
- Conditions
- Severe Mental Illness, Nicotine Dependence, Schizophrenia, Tobacco Use Disorder
- Trial name
- NCT01412866
- Testing
- EDSS with CO feedback and health checklist, EDSS with health checklist feedback alon
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Schizophrenia, Schizoaffective Disorder
Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia
This study is a six-week, randomized, placebo-controlled, fixed dose trial comparing cannabidiol Vs. placebo added to a stable dose of antipsychotic medications in patients diagnosed with schizophrenia.
- Trial name
- NCT00588731
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Yale University
Schizoaffective Disorder, Schizophrenia
Effectiveness of a Mobile Texting Intervention for People With Serious Mental Illness
Testing an mHealth mobile interventionist texting program on illness management.
- Conditions
- Schizoaffective Disorder, Schizophrenia, Bipolar Disorder, Major Depressive Disorder
- Trial name
- NCT03062267
- Testing
- Mobile Interventionist
- Where
- 2 sites in United States
- Volunteers
- 49 people
- Sponsor
- University of Washington
Schizophrenia
Anti-Inflammatory Treatment of Schizophrenia
Despite current antipsychotic treatment, the majority of people with schizophrenia continue to exhibit persistent positive and negative symptoms and cognitive impairments.
- Trial name
- NCT01514682
- Testing
- Anti-inflammatory Combination Therapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenia, Bipolar Disorder
A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children
The purpose of this study is to evaluate the effects of risperidone compared with other atypical antipsychotic drugs on the physical maturity, growth and development of children, and the risk of prolactin-related adverse events…
- Conditions
- Schizophrenia, Bipolar Disorder, Autistic Disorder, Conduct and Other Disruptive Behavior Disorders
- Trial name
- NCT01050582
- Testing
- Risperidone, Other atypical antipsychotic drugs
- Where
- 28 sites in United States, Belgium and 4 more
- Volunteers
- 244 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptom Patients Who Completed the Protocol 25543 (25544)(P05777)
This is an extension study to further test the efficacy and safety of asenapine compared with a marketed agent (olanzapine) in the treatment of patients with persistent negative symptoms of schizophrenia.
- Trial name
- NCT00265343
- Testing
- asenapine, olanzapine
- Volunteers
- 306 people
- Sponsor
- Organon and Co
Schizophrenia
An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia
This study aims to evaluate whether PF-02545920 is safe and effective in the treatment of acute exacerbation of schizophrenia during a 4-week inpatient treatment period.
- Trial name
- NCT01175135
- Testing
- PF-02545920, Risperidone
- Where
- 46 sites in United States, Germany and 1 more
- Volunteers
- 259 people
- Sponsor
- Pfizer
Schizophrenia
An Observational Study to Evaluate Efficacy and Safety of Risperidone Long-Acting Injection for Treatment of Schizophrenia
The purpose of this study is to evaluate the long-term treatment efficacy, and safety of risperidone long-acting injection in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability…
- Trial name
- NCT01894984
- Testing
- Risperidone, Oral atypical anti-psychotic
- Volunteers
- 640 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Schizophrenia
Nicotinic Receptors and Schizophrenia
The study determines if a new preparation of a drug designed to treat schizophrenia is more slowly released into the body.
- Trial name
- NCT00952393
- Testing
- Pharmacokinetic
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Schizophrenia, Dual Diagnosis
Cannabis and Schizophrenia: Self-Medication and Agonist Treatment
The first aim of this study is to determine whether a brain reward center (BRC) deficiency in patients with schizophrenia (SCZ) and cannabis use disorder (CUD) will be normalized when patients are given cannabis or dronabinol.
- Conditions
- Schizophrenia, Dual Diagnosis, Schizoaffective Disorder, Psychotic Disorder
- Trial name
- NCT00946348
- Testing
- Dronabinol, Cannabis
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Dartmouth-Hitchcock Medical Center
Schizophrenia
Effects of Galantamine on Cognition
Schizophrenia is a chronic disorder with onset of psychosis occurring in late teen early twenties, with cognitive impairments and negative symptoms frequently emerging much earlier.
- Trial name
- NCT01100775
- Testing
- Galantamine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenia
Antipsychotic Effects of Oxytocin
The objective of the study is to compare the efficacy of intranasal oxytocin versus intranasal placebo to improve symptoms in schizophrenia patients who have residual symptoms despite being on adequate treatment with…
- Trial name
- NCT01621737
- Testing
- Oxytocin
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- University of California, San Diego
Schizophrenia
Study of Aripiprazole in Patients With Schizophrenia- Effects on Glucose Metabolism-
The objective of this study is to examine the effects of aripiprazole on glucose metabolism in schizophrenic patients without hyperglycemia and diabetes mellitus or any history thereof.
- Trial name
- NCT00392197
- Testing
- Aripiprazole
- Where
- 5 sites in Japan
- Volunteers
- 111 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.